Ascendis Pharma (ASND) Prices 2M Share Offering at $150/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
September 23, 2024 5:11 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $191.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "We hosted an expert pediatric endocrinologist to discuss his views on ASNDs TransCon CNP in achondroplasia (ACH) following the recent topline ph 3 readout (see our Sep 16th note). Overall, our KOL was encouraged by the stat sig AGV... More
